Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | CTSG | P08311 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | CTRC | Q99895 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449456 | 0.93 | ALDH1A1 (0.66) | ALDH1A1MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL1021890 | 0.93 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL10008035 | 0.84 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2ATSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5965726 | 0.83 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL9055054 | 0.80 | MEN1 (0.61) | ALDH1A1MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL11776863 | 0.76 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL10031595 | 0.76 | KMT2A (0.66) | ALDH1A1MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL9975770 | 0.76 | KMT2A (0.66) | ALDH1A1MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL16759895 | 0.75 | KMT2A (0.70) | ALDH1A1MEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL16775234 | 0.75 | KMT2A (0.70) | ALDH1A1MEN1KMT2ATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092487-A1 | NOVEL 3,8-DIAZA-BICYCLO[3.2.1]OCTANE-AND 3,9-DIAZA-BICYCLO[3.3.1]-NONANE-3-CARBOXYLIC ACID ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-04-21 | — | — | US | disclosed |
| US-7910578-B2 | 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use | NEUROSEARCH A/S (DK) | 2011-03-22 | — | — | US | disclosed |
| EP-1863819-B1 | DIAZABICYCLIC ARYL DERIVATIVES AND THEIR USE AS CHINOLINERGIC LIGANDS AT THE NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH AS (DK) | 2011-01-12 | — | — | EP | disclosed |
| EP-1805183-B1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH AS (DK) | 2010-12-29 | — | — | EP | disclosed |
| US-7704991-B2 | Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-04-27 | — | — | US | disclosed |
| US-7662812-B2 | Diazabicyclic aryl derivatives and their use as chinolinergic ligands at nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2010-02-16 | — | — | US | disclosed |
| US-7612074-B2 | Diazabicyclic aryl derivatives as cholinergy ligands | NEUROSEARCH A/S (DK) | 2009-11-03 | — | — | US | disclosed |
| US-20090099153-A1 | NOVEL 8,10-DIAZA-BICYCLO[4.3.1]DECANE DERIVATIVES AND THEIR MEDICAL USE | ANIONA APS (DK) | 2009-04-16 | — | — | US | disclosed |
| EP-1819709-B1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGY LIGANDS | NEUROSEARCH AS (DK) | 2009-02-11 | — | — | EP | disclosed |
| US-20080280882-A1 | Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-11-13 | — | — | US | disclosed |
| WO-2006106090-A1 | NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-10-12 | — | — | WO | disclosed |
| EP-0460116-A4 | 9-SUBSTITUTED-8-UNSUBSTITUTED-9-DEAZAGUANINES | — | 1992-05-13 | — | — | EP | disclosed |
| EP-0288519-A4 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | — | 1992-04-15 | — | — | EP | disclosed |
| EP-0460116-A1 | 9-SUBSTITUTED-8-UNSUBSTITUTED-9-DEAZAGUANINES. | BIOCRYST (US) | 1991-12-11 | — | — | EP | disclosed |
| US-4965273-A | Certain 1-tertiary-butyl-naphthyridone carboxylic acid derivatives anti-bacterial agents | BRISTOL-MYERS COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| US-4954507-A | 1-tertiary-alkyl-substituted naphthyridine carboxylic acid antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0288519-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | Bristol-Myers Squibb Company (US) | 1988-11-02 | — | — | EP | disclosed |
| WO-1988002627-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-04-21 | — | — | WO | disclosed |
| US-3951980-A | 3-Substituted-8-methyl-3,8-diazabicyclo[3.2.1]octanes | STANFORD RESEARCH INSTITUTE (US) | 1976-04-20 | — | — | US | disclosed |
| US-3947445-A | Diazabicyclooctanes and diazabicycloheptanes | STANFORD RESEARCH INSTITUTE (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092487-A1 | NOVEL 3,8-DIAZA-BICYCLO[3.2.1]OCTANE-AND 3,9-DIAZA-BICYCLO[3.3.1]-NONANE-3-CARBOXYLIC ACID ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | ALDH1A1 354/4885MEN1 2207/4885KMT2A 2029/4885 |
| US-20090099153-A1 | NOVEL 8,10-DIAZA-BICYCLO[4.3.1]DECANE DERIVATIVES AND THEIR MEDICAL USE | CHRNA10, CHRNA7, CHRNA3 | ALDH1A1 1167/4885MEN1 3963/4885KMT2A 2568/4885 |
| US-20080280882-A1 | Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC6A3 | ALDH1A1 780/4885MEN1 1502/4885KMT2A 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.